[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Poncet G, Faucheron JL, Walter T: Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel. World J Gastroenterol; 2010 Apr 14;16(14):1696-706

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel.
  • Well-differentiated endocrine carcinomas of the small bowel are fairly rare neoplasms that present many clinical challenges.
  • Initial treatment aims to control carcinoid syndrome with somatostatin analogs.
  • Even if there is metastatic spread, surgical resection of the primitive tumor should be discussed in cases of retractile mesenteritis, small bowel ischemia or subocclusive syndrome in order to avoid any acute complication, in particular at the beginning of somatostatin analog treatment.
  • The choice of treatment depends on the symptoms, general health of the patient, tumor burden, degree of uptake of radionuclide, histological features of the tumor, and tumor growth.
  • Management strategies include surgery for cure (which is rarely achieved) or for cytoreduction, radiological interventions (transarterial embolization or radiofrequency ablation), and chemotherapy (interferon and somatostatin analogs).
  • New biological agent and radionuclide targeted therapies are under investigation.
  • Finally, it has to be emphasized that it is of the utmost importance to enroll these patients with a rare disease in prospective clinical trials assessing new therapeutic strategies.
  • [MeSH-major] Intestinal Neoplasms / therapy. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Algorithms. Carcinoid Tumor / diagnosis. Carcinoid Tumor / therapy. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / therapy. Humans. Intestine, Small. Malignant Carcinoid Syndrome / diagnosis. Malignant Carcinoid Syndrome / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endocrinol Invest. 2003;26(8 Suppl):14-6 [15233205.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:67-73 [15477721.001]
  • [Cites] N Engl J Med. 1967 Nov 23;277(21):1103-8 [6054996.001]
  • [Cites] Cancer Clin Trials. 1979 Winter;2(4):327-34 [93982.001]
  • [Cites] N Engl J Med. 1983 Jul 21;309(3):129-33 [6191217.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1255-9 [6238136.001]
  • [Cites] Am J Med. 1986 Dec 22;81(6B):41-8 [2432780.001]
  • [Cites] Am J Med. 1987 May 29;82(5B):77-83 [3035924.001]
  • [Cites] Anaesthesia. 1987 Jun;42(6):627-32 [2887127.001]
  • [Cites] Cancer. 1987 Dec 15;60(12):2891-5 [2960446.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):377-83; discussion 384-5 [2368441.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2624-30 [8384072.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):244-8 [8389666.001]
  • [Cites] Endocr Relat Cancer. 2008 Dec;15(4):1083-97 [18603570.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):338-45 [19118063.001]
  • [Cites] Neuroendocrinology. 2009;89(3):308-14 [19307732.001]
  • [Cites] Digestion. 2009;79(3):137-42 [19307736.001]
  • [Cites] Rev Endocr Metab Disord. 2009 Jun;10(2):91-102 [18642088.001]
  • [Cites] Nat Rev Endocrinol. 2009 Jul;5(7):382-93 [19488074.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Jul;6(7):429-33 [19561636.001]
  • [Cites] Neuroendocrinology. 2009;90(1):67-72 [19521065.001]
  • [Cites] Cancer. 2009 Aug 1;115(15):3392-9 [19472402.001]
  • [Cites] Aliment Pharmacol Ther. 2009 Oct;30(7):733-40 [19573169.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4635-6 [19704053.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4656-63 [19704057.001]
  • [Cites] Endocr Relat Cancer. 2009 Dec;16(4):1351-61 [19726540.001]
  • [Cites] J Clin Oncol. 2010 Jan 1;28(1):69-76 [19933912.001]
  • [Cites] Am J Clin Oncol. 2008 Jun;31(3):271-9 [18525307.001]
  • [Cites] Digestion. 2000;62 Suppl 1:79-83 [10940692.001]
  • [Cites] Ann Oncol. 2000 Sep;11(9):1127-30 [11061606.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3276-81 [11095353.001]
  • [Cites] J Surg Res. 2001 Jan;95(1):8-12 [11120628.001]
  • [Cites] Eur J Cancer. 2001 May;37(8):1014-9 [11334727.001]
  • [Cites] Cancer Control. 2001 Sep-Oct;8(5):454-60 [11579342.001]
  • [Cites] Surgery. 2001 Oct;130(4):677-82; discussion 682-5 [11602899.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):331-43 [11900219.001]
  • [Cites] Eur J Endocrinol. 2002 May;146(5):707-16 [11980628.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):614-21 [12056713.001]
  • [Cites] Expert Opin Pharmacother. 2002 Jun;3(6):643-56 [12472080.001]
  • [Cites] Eur Radiol. 2003 Jan;13(1):136-40 [12541121.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Radiology. 1993 Nov;189(2):541-7 [7692465.001]
  • [Cites] Endocrinol Metab Clin North Am. 1993 Dec;22(4):941-52 [8125079.001]
  • [Cites] Surgery. 1994 Dec;116(6):1111-6; discussion 1116-7 [7985095.001]
  • [Cites] Digestion. 1994;55 Suppl 3:92-7 [7698544.001]
  • [Cites] Am J Surg. 1995 May;169(5):523-8 [7747834.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):402-8 [8625251.001]
  • [Cites] Gut. 1996 Mar;38(3):430-8 [8675099.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):813-29 [9024720.001]
  • [Cites] Ann Oncol. 1997 Oct;8(10):1041-4 [9402179.001]
  • [Cites] Surgery. 1997 Dec;122(6):1147-54; discussion 1154-5 [9426432.001]
  • [Cites] Am J Surg. 1998 May;175(5):408-12 [9600289.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):372-8 [9669822.001]
  • [Cites] Transplantation. 1998 Nov 27;66(10):1307-12 [9846513.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):858-68 [10080850.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1381-7 [10235222.001]
  • [Cites] Acta Oncol. 2004;43(7):617-25 [15545182.001]
  • [Cites] Acta Oncol. 2004;43(7):626-36 [15545183.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2754-62 [15837990.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1717-51 [15887161.001]
  • [Cites] Gut. 2005 Jun;54 Suppl 4:iv1-16 [15888809.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):1083-92 [16322345.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):401-6 [16421420.001]
  • [Cites] J Interferon Cytokine Res. 2006 Jan;26(1):8-13 [16426143.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):461-6 [16364959.001]
  • [Cites] J Endocrinol Invest. 2005;28(11 Suppl International):21-7 [16625841.001]
  • [Cites] Nat Rev Drug Discov. 2006 Aug;5(8):671-88 [16883305.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1148-54 [17031397.001]
  • [Cites] Eur J Endocrinol. 2006 Dec;155(6):849-57 [17132755.001]
  • [Cites] Gastroenterol Clin Biol. 2006 Sep;30 Spec No 2:2S91-2S97 [17151568.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Feb;16(2):219-24 [17243941.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Apr;59(5):637-42 [16937105.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2986-91 [17505000.001]
  • [Cites] Virchows Arch. 2007 Oct;451(4):757-62 [17674042.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5609-15 [18065733.001]
  • [Cites] Neuroendocrinology. 2008;87(1):8-19 [18097129.001]
  • [Cites] Neuroendocrinology. 2008;87(1):47-62 [18097131.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):61-72 [18177818.001]
  • [Cites] J Clin Oncol. 2008 Mar 10;26(8):1316-23 [18323556.001]
  • [Cites] Ann Surg. 2008 Apr;247(4):659-65 [18362629.001]
  • [Cites] J Vasc Interv Radiol. 2008 Jun;19(6):855-61 [18503899.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3063-72 [18565894.001]
  • [Cites] J Clin Oncol. 2008 Jul 10;26(20):3403-10 [18612155.001]
  • [Cites] J Clin Oncol. 2008 Sep 10;26(26):4311-8 [18779618.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):1005-15 [12637610.001]
  • [Cites] Br J Surg. 2003 Jun;90(6):687-93 [12808615.001]
  • [Cites] J Am Coll Surg. 2003 Jul;197(1):29-37 [12831921.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2689-96 [12860945.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):463-8 [14713259.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):489-96 [14713263.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):966-73 [15151956.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2724-9 [15226340.001]
  • (PMID = 20380000.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 101
  • [Other-IDs] NLM/ PMC2852816
  •  go-up   go-down


2. Lau CP, Leung WK: Caecal metastasis from a primary small-cell lung carcinoma. Hong Kong Med J; 2008 Apr;14(2):152-3
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caecal metastasis from a primary small-cell lung carcinoma.
  • Small bowel metastases from a primary lung carcinoma are rare.
  • We report a case of a 59-year-old male with a primary small-cell lung carcinoma who developed anaemia and bowel symptoms.
  • On colonoscopic examination he was found to have a tumour in the caecum near the ileocaecal valve, which was biopsied, revealing small neuroendocrine tumour cells.
  • The patient then underwent systemic chemotherapy, which achieved a reduction in the size of the primary lung tumour and an improvement in his bowel symptoms.
  • It is important that such a rare condition be recognised early as complicated intestinal metastases from a lung carcinoma can lead to high mortality rates and poor short-term outcome.
  • With advances in chemotherapy and palliative care, patients with metastatic lung carcinoma can sometimes survive more than a year with reasonable quality of life.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382025.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


3. Shvartsbeyn M, Edelman MJ: Pemetrexed-induced typhlitis in non-small cell lung cancer. J Thorac Oncol; 2008 Oct;3(10):1188-90
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed-induced typhlitis in non-small cell lung cancer.
  • Food and Drug Administration-approved as a second line, single-agent treatment of recurrent metastatic non-small cell lung cancer.
  • In the premetrexed clinical trial database of 1327 patients, various types of colitis were reported by a total of nine patients (0.6%).
  • Typhilitis is a gastrointestinal complication of chemotherapy, which presents as fever and abdominal pain.
  • The diagnosis is supported by the findings of bowel wall thickening on computed tomographic imaging.
  • Typhilitis is usually seen in the setting of severe chemotherapy-induced neutropenia for acute leukemia.
  • Nevertheless, it is increasingly recognized as a complication of therapy in solid tumors.
  • We present the first documented case of typhilitis after treatment with pemetrexed and successful therapy with supportive treatment.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / adverse effects. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy. Typhlitis / chemically induced
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / complications. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / radiography. Adult. Female. Humans. Pemetrexed. Thymidylate Synthase / antagonists & inhibitors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827618.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


Advertisement
4. Meyer A, Bruns F, Richter K, Grünwald V, Karstens JH: Small cell cancer of the anal canal--case report of a rare tumor. Anticancer Res; 2007 Mar-Apr;27(2):1047-50
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell cancer of the anal canal--case report of a rare tumor.
  • BACKGROUND: We report on a rare case of small cell cancer located at the anal canal.
  • CASE REPORT: A 41-year old woman presented with locally advanced small cell anal cancer and simultaneous hepatic and pulmonal deposits.
  • Due to metastatic disease, chemotherapy with etoposide and cisplatin was performed with mixed response after four cycles of chemotherapy.
  • After application of two additional chemotherapy cycles, locally progressive disease occurred causing symptomatic bowel obstruction.
  • Despite adequate local treatment the patient's condition further deteriorated and irradiation was stopped.
  • CONCLUSION: In patients with metastatic small cell anal cancer chemotherapy remains the mainstay of therapy.
  • Careful histopathological examination, together with immunohistochemistry, is needed to determine the therapeutic strategy to be followed.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / therapy. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17465242.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


5. Hata K, Kitayama J, Shinozaki M, Komuro Y, Watanabe T, Takano T, Iwase S, Nagawa H: Intestinal perforation due to metastasis of breast carcinoma, with special reference to chemotherapy: a case report. Jpn J Clin Oncol; 2001 Apr;31(4):162-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal perforation due to metastasis of breast carcinoma, with special reference to chemotherapy: a case report.
  • We report a case of small-bowel perforation due to metastatic carcinoma of the breast during chemotherapy.
  • Partial resection of the small intestine and primary anastomosis were performed.
  • Since perforation during chemotherapy results in an extremely poor prognosis, special caution during chemotherapy is needed for patients with possible gastrointestinal involvement with tumor.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma, Scirrhous / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Intestinal Neoplasms / secondary. Intestinal Perforation / etiology. Intestine, Small. Neoplasms, Multiple Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11386463.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Polyzos A, Kouraklis G, Giannopoulos A, Bramis J, Delladetsima JK, Sfikakis PP: Irinotecan as salvage chemotherapy for advanced small bowel adenocarcinoma: a series of three patients. J Chemother; 2003 Oct;15(5):503-6
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irinotecan as salvage chemotherapy for advanced small bowel adenocarcinoma: a series of three patients.
  • Small bowel adenocarcinoma (SBA) is a relatively rare disease.
  • Because of its rarity the role of chemotherapy either as adjuvant or for advanced disease has not been clearly defined.
  • Two patients with positive lymph nodes received postoperative adjuvant chemotherapy with 5-fluorouracil-folinic acid (5FU-FA) for 12 months but they developed metastatic disease 3 and 8 months later, respectively.
  • The third patient was initially treated with the same agents but for metastatic disease.
  • All patients were subsequently treated for tumor recurrence with irinotecan 350 mg/m2 i.v. every 3 weeks as salvage chemotherapy supported by Granulocyte Colony Stimulating Factor (GCSF) for 5 days.
  • Their survival times after irinotecan administration were 14 and 6 months with an overall survival after primary diagnosis of 29 and 27 months, respectively.
  • Although conclusions cannot be drawn regarding the role of adjuvant chemotherapy in SBA, it seems reasonable to extrapolate from large bowel carcinoma experience.
  • Irinotecan seems to have some degree of activity in the treatment of SBA but further studies are warranted.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Ileal Neoplasms / drug therapy. Jejunal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Disease Progression. Drug Resistance, Neoplasm. Humans. Male. Salvage Therapy. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14598944.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Clemente G, Chiarla C, Giovannini I, De Rose AM, Astone A, Barone C, Nuzzo G: Gas in portal circulation and pneumatosis cystoides intestinalis during chemotherapy for advanced rectal cancer. Curr Med Res Opin; 2010 Mar;26(3):707-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gas in portal circulation and pneumatosis cystoides intestinalis during chemotherapy for advanced rectal cancer.
  • OBJECTIVES: Acute abdominal symptoms with CT scan evidence of intramural gas in bowel walls (pneumatosis cystoides intestinalis, PCI) and of gas in the portal venous blood (PBG) in patients undergoing chemotherapy may represent a worrisome picture, suggestive of bowel necrosis.
  • We describe a patient with acute abdominal symptoms and evidence of PCI with PBG under cetuximab, oxaliplatin, tegafur-uracil and folinic acid chemotherapy for metastatic adenocarcinoma of the rectosigmoid junction.
  • METHODS: After admission for mucositis with diarrhea and profound dehydration, and subsequent emergency laparotomy for derotation of an intestinal volvulus, on the tenth postoperative day the patient developed fever and abdominal pain, with CT scan evidence of PCI with PBG.
  • The exam of the abdomen did not suggest major problems requiring emergency surgery, and antibiotic treatment with close monitoring were performed, followed by rapid improvement.
  • RESULTS: Twelve days later, after resumption of oral diet, the patient unexpectedly suffered a spontaneous jejunal microperforation, requiring emergency laparotomy and bowel resection.
  • Pathology showed that the perforation was within an area of ulceration involving the inner superficial layer of the bowel.
  • Subsequently recovery was normal and at present, after 15 months, the patient is well and continuing chemotherapy.
  • CONCLUSIONS: This is probably the first report of PCI with PBG related to intestinal toxicity during cetuximab, oxaliplatin, tegafur-uracil and folinic acid chemotherapy in a patient with advanced rectal carcinoma, followed by delayed small bowel perforation.
  • It provides an example of the challenges involved in the management of this type of patient.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Gases. Pneumatosis Cystoides Intestinalis. Portal Vein / pathology
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Cetuximab. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Rectal Neoplasms / drug therapy. Rectal Neoplasms / pathology. Tegafur / administration & dosage. Tegafur / adverse effects

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20078321.001).
  • [ISSN] 1473-4877
  • [Journal-full-title] Current medical research and opinion
  • [ISO-abbreviation] Curr Med Res Opin
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Gases; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 1548R74NSZ / Tegafur; PQX0D8J21J / Cetuximab; Q573I9DVLP / Leucovorin
  •  go-up   go-down


8. Gray J, Murren J, Sharma A, Kelley S, Detterbeck F, Bepler G: Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab. J Thorac Oncol; 2007 Jun;2(6):571-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab.
  • Bowel metastasis and perforation in patients with non-small cell lung cancer is rare.
  • Bevacizumab has emerged as a new therapy in the treatment of metastatic non-small cell lung cancer.
  • Bowel perforation associated with its use has been described in colon and ovarian cancers.
  • In this report, we present the first known case of visceral perforation in a patient with metastatic non-small cell lung cancer after treatment with bevacizumab.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Gastrointestinal Neoplasms / drug therapy. Intestinal Perforation / etiology. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545855.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


9. Lerouge D, Touboul E, Lefranc JP, Uzan S, Jannet D, Moureau-Zabotto L, Genestie C, Antoine M, Jamali M: [Preoperative concurrent radiation therapy and chemotherapy for operable bulky carcinomas of uterine cervix stages IB2, IIA, and IIB with proximal parametrial invasion]. Cancer Radiother; 2004 Jun;8(3):168-77
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperative concurrent radiation therapy and chemotherapy for operable bulky carcinomas of uterine cervix stages IB2, IIA, and IIB with proximal parametrial invasion].
  • [Transliterated title] Association concomitante préopératoire de radiothérapie et de chimiothérapie dans les cancers du col utérin opérables de stades IB2, IIA et IIB proximal de gros volume.
  • All patients underwent preoperative external beam pelvic radiation therapy (EBPRT) and concomitant chemotherapy during the first and the fourth radiation weeks combining 5-fluorouracil and cisplatin.
  • The pelvic dose was 40.50 Gy over 4.5 weeks.
  • EBPRT was followed by low-dose-rate uterovaginal brachytherapy with a total dose of 20 Gy in 17 pts.
  • Twenty-one of 25 pts who had not received preoperative uterovaginal brachytherapy underwent postoperative low-dose-rate vaginal brachytherapy of 20 Gy.
  • The 5-year local control rate and metastatic failure rate were 90% and 83.5%, respectively.
  • However, six pts had grade 3 acute intestinal toxicity.
  • Four severe late complications requiring surgical intervention were observed (one small bowel complication, three ureteral complications).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / radiotherapy. Neoplasm Invasiveness. Neoplasm Staging. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Brachytherapy. Cisplatin / administration & dosage. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Neoadjuvant Therapy. Radiation Injuries. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15217584.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Scabini S, Rimini E, Romairone E, Scordamaglia R, Boggio M, Musizzano Y, Ferrando V: Small bowel metastasis from primary neuroendocrine small cell lung carcinoma. Chir Ital; 2009 Sep-Dec;61(5-6):679-82
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel metastasis from primary neuroendocrine small cell lung carcinoma.
  • Small bowel metastases from a primary lung carcinoma are rare.
  • We report a case of a 76-year-old male with a primary neuroendocrine small cell carcinoma of the lung, treated by chemotherapy, who developed fever and bowel symptoms (subocclusion and pain).
  • On CT examination, he was found to have a tumour in the small bowel.
  • At operation we found small bowel occlusion by neoplasia and we therefore resected 15 cm of ileum with a side-to-side anastomosis.
  • Early recognition of this rare condition is important due to the fact that complicated intestinal metastases from lung carcinoma can lead to high mortality rates and poor short-term outcomes.
  • With advances in chemotherapy and palliative care, patients with metastatic lung carcinoma can sometimes survive more than a year with a reasonable quality of life.
  • [MeSH-major] Carcinoma, Neuroendocrine / secondary. Carcinoma, Neuroendocrine / surgery. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / surgery. Ileal Neoplasms / secondary. Ileal Neoplasms / surgery. Lung Neoplasms / pathology
  • [MeSH-minor] Aged. Anastomosis, Surgical. Humans. Laparotomy. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20380277.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Gücer F, Oz-Puyan F, Yilmaz O, Mülayim N, Balkanli-Kaplan P, Yüce MA: Endometrial carcinoma with laparotomy wound recurrence: complete remission following surgery and chemotherapy consisting of paclitaxel and carboplatin. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1195-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma with laparotomy wound recurrence: complete remission following surgery and chemotherapy consisting of paclitaxel and carboplatin.
  • We present a patient with surgical stage I endometrial cancer who experienced laparotomy wound recurrence 4 years after primary treatment.
  • She was treated successfully by complete surgical resection of recurrent tumors and chemotherapy.
  • A 62-year-old white female with laparotomy wound recurrence of endometrial carcinoma with small-bowel involvement and concomitant subcutaneous metastasis in the abdominal wall underwent complete surgical resection of metastatic tumors followed by six cycles of chemotherapy consisting of paclitaxel (175 mg/m2) and carboplatin (area under the curve 5).
  • Endometrial carcinoma with laparotomy wound recurrences, especially those with concomitant metastases, can be successfully treated by complete surgical resection followed by chemotherapy consisting of paclitaxel and carboplatin.
  • [MeSH-major] Carcinoma, Endometrioid / therapy. Endometrial Neoplasms / therapy. Intestinal Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carboplatin / administration & dosage. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Paclitaxel / administration & dosage. Remission Induction. Surgical Procedures, Operative. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343212.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


12. Schellhaas E, Loddenkemper C, Schmittel A, Buhr HJ, Pohlen U: Bowel perforation in non-small cell lung cancer after bevacizumab therapy. Invest New Drugs; 2009 Apr;27(2):184-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowel perforation in non-small cell lung cancer after bevacizumab therapy.
  • BACKGROUND: Bevacizumab is increasingly used in combination with chemotherapy for treatment of unresectable non-small cell lung cancer.
  • The aim of this report is to underline possible risks associated with this otherwise well-tolerated drug.
  • PATIENT: A 69-year-old patient with metastatic non-small cell lung cancer was started on a palliative chemotherapy regimen containing carboplatin, paclitaxel, and bevacizumab.
  • RESULTS: After the second cycle of chemotherapy, the patient developed abdominal pain.
  • On emergency laparotomy, there was diffuse perforation of the colonic wall, so the patient underwent a Hartmann's procedure with subtotal colectomy.
  • CONCLUSION: Gastrointestinal perforation is a known adverse event of bevacizumab therapy which so far has occurred only in patients with predisposing risk factors.
  • Our patient illustrates that there must always remain a high index of suspicion regarding bowel perforation in patients developing acute abdominal pain under bevacizumab therapy, even if they have no apparent risk factors.
  • [MeSH-major] Angiogenesis Inhibitors / adverse effects. Antibodies, Monoclonal / adverse effects. Carcinoma, Non-Small-Cell Lung / complications. Intestinal Perforation / chemically induced. Lung Neoplasms / complications
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Carboplatin / administration & dosage. Carboplatin / therapeutic use. Humans. Male. Paclitaxel / administration & dosage. Paclitaxel / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):118-23 [17658587.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):3-6 [17383545.001]
  • [Cites] Oncologist. 2007 Jun;12(6):713-8 [17602060.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] BMC Cancer. 2007 May 30;7:91 [17537235.001]
  • [Cites] J Thorac Oncol. 2007 Jun;2(6):571-3 [17545855.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2729-35 [17363594.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1539-44 [17442997.001]
  • [Cites] Clin Ther. 2006 Nov;28(11):1779-802 [17212999.001]
  • [Cites] Oncology. 2005;69 Suppl 3:25-33 [16301833.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1295-8 [16503384.001]
  • [Cites] J Med Case Rep. 2008 Feb 13;2:47 [18271967.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):83-9 [16736514.001]
  • [Cites] Chirurg. 2008 Apr;79(4):351-5 [17453167.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):1961-70 [17404076.001]
  • [Cites] J Surg Oncol. 2008 Feb 1;97(2):180-5 [18095268.001]
  • (PMID = 18665327.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


13. Myerson RJ, Valentini V, Birnbaum EH, Cellini N, Coco C, Fleshman JW, Gambacorta MA, Genovesi D, Kodner IJ, Picus J, Ratkin GA, Read TE: A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma. Int J Radiat Oncol Biol Phys; 2001 Aug 1;50(5):1299-308
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma.
  • BACKGROUND: Improving the response to preoperative therapy may increase the likelihood of successful resection of locally advanced rectal cancers.
  • Historically, the pathologic complete response (pCR) rate has been < approximately 10% with preoperative radiation therapy alone and < approximately 20% with concurrent chemotherapy and radiation therapy.
  • METHODS AND MATERIALS: Thirty-seven patients were enrolled on a prospective Phase I/II protocol conducted jointly at Washington University, St. Louis and the Catholic University of the Sacred Heart, Rome evaluating a three-dimensionally (3D) planned boost as part of the preoperative treatment of patients with unresectable or recurrent rectal cancer.
  • Preoperative treatment consisted of 4500 cGy in 25 fractions over 5 weeks to the pelvis, with a 3D planned 90 cGy per fraction boost delivered once or twice a week concurrently (no time delay) with the pelvic radiation.
  • The boost treatment was twice a week (total boost dose 900 cGy) if small bowel could be excluded from the boost volume, otherwise the boost was delivered once a week (total boost dose 450 cGy).
  • Twenty-seven underwent proctectomy; reasons for unresectability included persistent locally advanced disease (6 cases) and progressive distant metastatic disease with stable or smaller local disease (4 cases).
  • The most important factor for pCR was tumor volume: small lesions with planning target volume (PTV) < 200 cc showed a 50% pCR rate (p = 0.02).
  • There were no treatment associated fatalities.
  • Nine of the 37 patients (24%) experienced Grade 3 or 4 toxicities (usually proctitis) during preoperative treatment.
  • The most important factors for small bowel toxicity (acute or late) were small bowel volume (> or = 150 cc at doses exceeding 4000 cGy) and large tumor (PTV > or = 800 cc).
  • CONCLUSION: 3D planned boost therapy is feasible.
  • In addition to permitting the use of nonaxial beams for improved dose distributions, 3D planning provides tumor and normal tissue dose-volume information that is important in interpreting outcome.
  • Every effort should be made to limit the treated small bowel to less than 150 cc.
  • Tumor size is the most important predictor of response, with small lesions of PTV < 200 cc most likely to develop complete responses.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Antimetabolites, Antineoplastic / therapeutic use. Fluorouracil / therapeutic use. Imaging, Three-Dimensional. Neoadjuvant Therapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Adjuvant. Radiotherapy, High-Energy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colectomy. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Intestine, Small / radiation effects. Male. Middle Aged. Missouri / epidemiology. Neoplasm Invasiveness. Pelvis / radiation effects. Proctitis / epidemiology. Proctitis / etiology. Prospective Studies. Radiation Injuries / epidemiology. Radiation Injuries / etiology. Remission Induction. Rome / epidemiology. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11483342.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Fury MG, Sherman E, Stambuk H, Haque S, Lisa D, Shen R, Carlson D, Pfister DG: Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):e14527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 24 patients enrolled: 13 M, 11F; median age 62 (32-77); median number of prior cytotoxic chemotherapy regimens 1 (0-3; 75% with prior RT).
  • At DL1, 3 patients were inevaluable (1 withdrawal of consent prior to treatment, 1 disease progression during cycle 1, 1 recurrent diverticulitis during cycle 1) and were replaced.
  • DL 1 was expanded after a patient with melanoma metastatic to liver had sudden death of unclear cause, and the protocol was amended to exclude patients with hepatic dysfunction.
  • At DL2, one patient experienced grade 3 small bowel obstruction of uncertain etiology, and the dose level was expanded to 6 evaluable patients without additional DLT.
  • Minor response seen in pulmonary carcinoid (n = 1); prolonged SD ≥ 6 cycles seen in pulmonary carcinoid (n=2), basal cell carcinoma (n=1), and esthesioneuroblastoma (n=1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Childs AJ, Burke JJ 2nd, Perry MY, Gallup DG: Metastatic uterine serous carcinoma originating in an endometrial polyp: a report of 2 cases. J Reprod Med; 2005 Mar;50(3):209-12
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic uterine serous carcinoma originating in an endometrial polyp: a report of 2 cases.
  • BACKGROUND: Endometrial carcinoma is the most common cancer of the female genital tract.
  • Two histologic variants have been described: an estrogen-dependent form and a more aggressive, non-estrogen-dependent form, which includes uterine serous carcinoma.
  • CASES: Two cases of uterine serous carcinoma were confined to an endometrial polyp without myometrial invasion and were widely metastatic.
  • At the time of surgery, these patients were found to have extensive carcinomatosis and underwent surgical staging procedures that required bowel resections.
  • Pathology showed metastatic disease originating in a small focus of serous adenocarcinoma at the tip of an endometrial polyp.
  • Combination chemotherapy was planned; but 1 of the patients died prior to its initiation.
  • CONCLUSION: These cases emphasize the aggressive nature of uterine serous carcinoma despite insignificant myometrial invasion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841935.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Ortega J, Hayes JM, Antonia S: Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literature. Cancer Chemother Pharmacol; 2009 Dec;65(1):187-90
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literature.
  • It is most commonly caused by bowel necrosis and typically carries a grave prognosis.
  • Bevacizumab has emerged as an effective standard therapy in the frontline management of advanced non-small cell lung cancer (NSCLC).
  • CASE: A 75-year-old man, diagnosed with metastatic NSCLC, was treated with palliative chemotherapy consisting of paclitaxel, carboplatin, and bevacizumab for six cycles.
  • CONCLUSION: This is the first case of HPVG associated with bevacizumab therapy in a patient with metastatic NSCLC.
  • The HPVG may have been an early warning sign of impending bowel perforation, and bevacizumab was immediately discontinued, with HPVG completely resolving on follow-up CT scan 2 weeks later.
  • We recommend that bevacizumab therapy be immediately and permanently discontinued whenever HPVG is observed, as this may help avoid a potentially catastrophic outcome.
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Follow-Up Studies. Humans. Intestinal Perforation / chemically induced. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Male. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697030.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K24 CA128953
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


17. Regine WF, Hanna N, Garofalo MC, Doyle A, Arnold S, Kataria R, Sims J, Tan M, Mohiuddin M: Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm. Int J Radiat Oncol Biol Phys; 2007 May 1;68(1):172-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm.
  • PURPOSE: To determine the maximum tolerated dose of upper abdominal low-dose fractionated radiotherapy (<1.0 Gy per fraction) given in combination with, and as a chemopotentiator for, gemcitabine.
  • Ten patients have been entered in Phase I: 6 with metastatic/recurrent pancreatic carcinoma and 4 with unresectable pancreatic/small bowel carcinoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / radiotherapy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Dose Fractionation. Drug Administration Schedule. Female. Humans. Intestine, Small. Male. Middle Aged. Radiation-Sensitizing Agents / adverse effects. Radiation-Sensitizing Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17276612.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


18. Okubo K, Yoshioka S, Asukai K, Hata T, Nakanishi M, Maekawa T, Hama N, Kashiwazaki M, Taniguchi M, Tsujie M, Konishi M, Yano K, Fujimoto T: [A case report of primary adenocarcinoma of small intestine]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2792-4
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of primary adenocarcinoma of small intestine].
  • This is an account of a case of primary adenocarcinoma of the small intestine with peritoneal dissemination successfully treated with chemotherapy.
  • Abdominal computerized tomography revealed a bowel obstruction with tumor and the remarkable small bowel dilation of oral side of tumor.
  • Peritoneal dissemination was recognized around the ileocecal region, so ileum partial resection was performed for the primary cancer lesion and dissemination region.
  • The peritoneal dissemination consisted of metastatic adenocarcinoma from small intestine.
  • After an operation, internal use of S-1 was performed as adjuvant chemotherapy.
  • For lung metastasis, the combination chemotherapy with mFOLFOX6 + bevacizumab was administered.
  • Primary small intestinal adenocarcinoma is a rare disease, and it is often diagnosed as advanced cancer because of few characteristic symptoms.
  • So carcinoma of the small intestine usually has a poor prognosis.
  • [MeSH-major] Adenocarcinoma / therapy. Intestinal Neoplasms / therapy
  • [MeSH-minor] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bevacizumab. Combined Modality Therapy. Drug Combinations. Female. Fluorouracil / administration & dosage. Humans. Ileal Neoplasms / drug therapy. Leucovorin / administration & dosage. Lymphatic Metastasis. Middle Aged. Organoplatinum Compounds / administration & dosage. Ovarian Neoplasms / secondary. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224715.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Organoplatinum Compounds; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 2S9ZZM9Q9V / Bevacizumab; 5VT6420TIG / Oxonic Acid; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


19. Miller ES, Hoekstra AV, Hurteau JA, Rodriguez GC: Cardiac metastasis from poorly differentiated carcinoma of the cervix: a case report. J Reprod Med; 2010 Jan-Feb;55(1-2):78-80
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac metastasis from poorly differentiated carcinoma of the cervix: a case report.
  • BACKGROUND: Disease metastatic to the heart from cervical carcinoma is rare and associated with a poor prognosis.
  • Multimodality treatment has been shown to provide palliative benefit.
  • CASE: A woman presented with stage Ib2 cervical cancer metastatic to the tricuspid valve.
  • She presented with small bowel obstruction from a small bowel metastasis 4 years after initial treatment with chemoradiation.
  • Computed tomographic imaging revealed a small bowel mass as well as a pericardial effusion.
  • Endomyocardial biopsy confirmed metastatic disease consistent with a cervical primary.
  • The patient was treated with bowel resection, systemic chemotherapy and cardiac radiation.
  • CONCLUSION: Cervical cancer metastatic to the heart is rare and associated with a poor prognosis.
  • Selected patients may benefit from multimodality treatment.
  • [MeSH-major] Carcinoma / secondary. Heart Neoplasms / secondary. Tricuspid Valve / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Fatal Outcome. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20337214.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Hillenbrand A, Sträter J, Henne-Bruns D: Frequency, symptoms and outcome of intestinal metastases of bronchopulmonary cancer. Case report and review of the literature. Int Semin Surg Oncol; 2005 Jun 6;2:13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency, symptoms and outcome of intestinal metastases of bronchopulmonary cancer. Case report and review of the literature.
  • BACKGROUND: We report a new case of small bowel metastases from primary lung cancer.
  • CASE PRESENTATION: The case involved a 56-year-old man with a squamous cell carcinoma of the lung (stage IV) that had been treated with chemotherapy.
  • Postoperative pathologic analysis confirmed the diagnosis of metastatic pulmonary carcinoma.
  • Most cases presented with bowel perforation or obstruction.
  • Squamous cell carcinoma was the most common histological cell type followed by large cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 1961 May;49:687-9 [13772590.001]
  • [Cites] Rev Pneumol Clin. 2003 Jun;59(3):161-5 [13130203.001]
  • [Cites] Mt Sinai J Med. 2003 Mar;70(2):130-2 [12634905.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Surg Today. 2001;31(4):358-62 [11321350.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):227-8 [10623713.001]
  • [Cites] Am J Gastroenterol. 1999 Jul;94(7):1884-7 [10406253.001]
  • [Cites] Acta Chir Belg. 1992 Jul-Aug;92(4):187-90 [1414135.001]
  • [Cites] J Surg Oncol. 1992 Dec;51(4):287-91 [1434663.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 2003 Aug;41(8):537-40 [14503339.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2003 Dec;13(6):397-400 [14733704.001]
  • [Cites] Am Surg. 1992 Nov;58(11):677-82 [1485699.001]
  • [Cites] Kyobu Geka. 1991 Jul;44(7):596-9 [1886324.001]
  • [Cites] Arch Surg. 1990 May;125(5):583-5 [2158777.001]
  • [Cites] Can J Surg. 1979 Jul;22(4):351-3 [222418.001]
  • [Cites] Conn Med. 1989 Aug;53(8):455-6 [2670420.001]
  • [Cites] Cancer. 1987 Apr 15;59(8):1486-9 [3028602.001]
  • [Cites] Mil Med. 1988 Jan;153(1):30-2 [3126420.001]
  • [Cites] J Clin Gastroenterol. 1987 Oct;9(5):563-7 [3680909.001]
  • [Cites] Postgrad Med J. 1985 Feb;61(712):163-5 [3983047.001]
  • [Cites] J Can Assoc Radiol. 1974 Sep;25(3):242-4 [4424984.001]
  • [Cites] Cancer. 1972 Sep;30(3):806-9 [5075363.001]
  • [Cites] Am J Gastroenterol. 1969 Feb;51(2):145-50 [5776147.001]
  • [Cites] Am J Gastroenterol. 1980 Dec;74(6):504-6 [6259933.001]
  • [Cites] Acta Gastroenterol Belg. 1996 Jul-Sep;59(3):217-9 [9015935.001]
  • [Cites] J Chir (Paris). 1996 Sep;133(6):290-3 [8949275.001]
  • [Cites] Cancer. 1977 Jul;40(1):410-5 [880569.001]
  • [Cites] Kyobu Geka. 1995 Feb;48(2):169-71 [7897891.001]
  • [Cites] Acta Chir Belg. 2001 Nov-Dec;101(6):300-3 [11868507.001]
  • [Cites] Ann Surg. 1981 Jan;193(1):67-9 [7458451.001]
  • [Cites] Clin Oncol. 1980 Jun;6(2):181-6 [7408284.001]
  • [Cites] J Surg Oncol. 1983 Jun;23(2):93-4 [6855247.001]
  • [Cites] Ann Surg. 1983 Jan;197(1):120 [6848049.001]
  • [Cites] Endoscopy. 1994 Nov;26(9):752-3 [7712974.001]
  • (PMID = 15938753.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1180466
  •  go-up   go-down


21. Heimann DM, Schwartzentruber DJ: Gastrointestinal perforations associated with interleukin-2 administration. J Immunother; 2004 May-Jun;27(3):254-8
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-dose interleukin-2 (IL-2) results in objective clinical regression in up to 17% of patients with metastatic melanoma and renal cell carcinoma, with about half of these patients experiencing a complete regression of all lesions.
  • A retrospective review of all patients treated with IL-2 in the Surgery Branch of the National Cancer Institute (NCI) between Nov.
  • In addition, a review of the published English literature on GI perforation in conjunction with IL-2 therapy was performed.
  • These patients developed various signs and symptoms of GI perforation.
  • Six patients developed abdominal pain, yet only two of the eight patients had a fever.
  • The location of the perforation included the stomach, small bowel, appendix, and colon.
  • All underwent surgical treatment successfully, and four patients received further IL-2 therapy after recovering from the perforation.
  • The key to early diagnosis of GI perforation during IL-2 therapy is radiographic evaluation.
  • Patients with GI perforation can be safely retreated with IL-2 if they are given adequate time to recover from their surgical intervention and if careful assessment is performed to rule out residual infection.
  • [MeSH-major] Digestive System / drug effects. Interleukin-2 / adverse effects. Interleukin-2 / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carcinoma, Renal Cell / drug therapy. Female. Gastrointestinal Diseases / etiology. Humans. Male. Melanoma / drug therapy. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15076143.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2
  • [Number-of-references] 20
  •  go-up   go-down






Advertisement